Vitrolife AB (VITR) - Total Liabilities
Based on the latest financial reports, Vitrolife AB (VITR) has total liabilities worth Skr3.17 Billion SEK (≈ $341.25 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Vitrolife AB - Total Liabilities Trend (2000–2025)
This chart illustrates how Vitrolife AB's total liabilities have evolved over time, based on quarterly financial data. See Vitrolife AB current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Vitrolife AB Competitors by Total Liabilities
The table below lists competitors of Vitrolife AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shandong Yisheng Livestock & Poultry Breeding Co Ltd
SHE:002458
|
China | CN¥3.02 Billion |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
|
China | CN¥1.65 Billion |
|
Polestar Automotive Holding UK PLC Class A ADS
NASDAQ:PSNY
|
USA | $7.91 Billion |
|
M Yochananof and Sons Ltd
TA:YHNF
|
Israel | ILA2.87 Billion |
|
Zhiyang Innovation Technology Co. Ltd. A
SHG:688191
|
China | CN¥612.56 Million |
|
Paymentus Holdings, Inc.
NYSE:PAY
|
USA | $115.11 Million |
|
Zhejiang Huangma Technology Co Ltd
SHG:603181
|
China | CN¥927.28 Million |
|
Alimak Hek Group AB
ST:ALIG
|
Sweden | Skr6.23 Billion |
Liability Composition Analysis (2000–2025)
This chart breaks down Vitrolife AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Vitrolife AB (VITR) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.68 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vitrolife AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vitrolife AB (2000–2025)
The table below shows the annual total liabilities of Vitrolife AB from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr3.23 Billion ≈ $347.49 Million |
-15.14% |
| 2024-12-31 | Skr3.81 Billion ≈ $409.48 Million |
+5.52% |
| 2023-12-31 | Skr3.61 Billion ≈ $388.06 Million |
-5.38% |
| 2022-12-31 | Skr3.81 Billion ≈ $410.12 Million |
-6.77% |
| 2021-12-31 | Skr4.09 Billion ≈ $439.93 Million |
+1319.05% |
| 2020-12-31 | Skr288.07 Million ≈ $31.00 Million |
-15.54% |
| 2019-12-31 | Skr341.06 Million ≈ $36.70 Million |
+69.47% |
| 2018-12-31 | Skr201.25 Million ≈ $21.66 Million |
+3.86% |
| 2017-12-31 | Skr193.78 Million ≈ $20.85 Million |
-15.79% |
| 2016-12-31 | Skr230.11 Million ≈ $24.76 Million |
+7.39% |
| 2015-12-31 | Skr214.27 Million ≈ $23.06 Million |
-20.61% |
| 2014-12-31 | Skr269.91 Million ≈ $29.05 Million |
+63.38% |
| 2013-12-31 | Skr165.21 Million ≈ $17.78 Million |
-9.83% |
| 2012-12-31 | Skr183.22 Million ≈ $19.72 Million |
+49.11% |
| 2011-12-31 | Skr122.88 Million ≈ $13.22 Million |
+19.23% |
| 2010-12-31 | Skr103.06 Million ≈ $11.09 Million |
+118.12% |
| 2009-12-31 | Skr47.25 Million ≈ $5.08 Million |
-6.02% |
| 2008-12-31 | Skr50.27 Million ≈ $5.41 Million |
+9.11% |
| 2007-12-31 | Skr46.08 Million ≈ $4.96 Million |
-8.57% |
| 2006-12-31 | Skr50.40 Million ≈ $5.42 Million |
+44.32% |
| 2005-12-31 | Skr34.92 Million ≈ $3.76 Million |
-0.13% |
| 2004-12-31 | Skr34.96 Million ≈ $3.76 Million |
-13.80% |
| 2003-12-31 | Skr40.56 Million ≈ $4.36 Million |
-47.40% |
| 2002-12-31 | Skr77.11 Million ≈ $8.30 Million |
-10.65% |
| 2001-12-31 | Skr86.30 Million ≈ $9.29 Million |
+114.93% |
| 2000-12-31 | Skr40.15 Million ≈ $4.32 Million |
-- |
About Vitrolife AB
Vitrolife AB (publ) provides assisted reproduction products in Europe, the Middle East, Africa, Asia-Pacific, and the Americas. It offers sperm processing, oocyte retrieval needles, micromanipulation pipettes, time-lapse systems, and evaluation tools, laser and imaging systems, IVF media and oil, embryo transfer, cryopreservation, and genomics kits. The company also provides eWitness and Labware … Read more